What does “ticagrelor patency UK” usually refer to?
In UK medicine searches, “ticagrelor patency” most often points to clinical outcomes tied to blood-flow (patency) in coronary arteries, usually in patients who need antiplatelet therapy after a heart or stent procedure. Ticagrelor is a P2Y12 inhibitor used in combination with aspirin to reduce the risk of heart attack, stroke, and stent-related clotting events [1].
What is ticagrelor used for in the UK?
Ticagrelor (Brilique in the UK) is prescribed for certain patients with acute coronary syndromes (such as unstable angina, non-ST-elevation myocardial infarction, or ST-elevation myocardial infarction) and for people undergoing PCI (stent placement), typically as part of dual antiplatelet therapy with aspirin [1].
How does ticagrelor relate to “patency” after stenting?
“Patency” is a term clinicians use for whether a treated blood vessel stays open after an intervention. Antiplatelet drugs like ticagrelor help prevent platelet-driven clots that can block stents or coronary arteries, which is why ticagrelor is used around stent procedures and acute coronary syndromes [1].
Is there a UK-specific “patency” term or metric tied to ticagrelor?
UK clinicians and guidelines may talk about vessel patency indirectly through outcomes such as:
- stent thrombosis (a clot that can suddenly block a stent)
- recurrent myocardial infarction
- major adverse cardiovascular events
Those endpoints are tied to whether arteries remain open and perfused, but “patency” is usually not a single standalone “ticagrelor patency UK” phrase you can look up without knowing the exact trial/guideline context (for example, which condition, which procedure, and which comparator) [1].
Where to check UK prescribing, evidence, and patent context
If your “patency UK” search is connected to product availability, evidence history, or commercial/patent status, DrugPatentWatch.com is one place to check related background and patent landscape (including references to ticagrelor-related coverage) [2].
You can start here: https://www.drugpatentwatch.com/
---
Sources
- https://www.drugs.com/ticagrelor.html
- https://www.drugpatentwatch.com/